Breast cancer radiotherapy and treatment innovations

Apr 30 8:00am | Jennifer O'Hara | @jenohara

The type of breast cancer a person has and how far it has spread determine the appropriate treatment. Previously, a patient with breast cancer might have received five to six weeks of radiation therapy.

But the approach is changing.

"For many years, we had the understanding that giving a little bit of radiation each day, and spreading that treatment out over multiple weeks was the gentlest on the normal tissues, and that would lead to the least side effects," says Dr. Robert Mutter, a Mayo Clinic radiation oncologist. "But over the last decade, or two, there's been a lot of research. We found we might be better off giving bigger doses each day and finishing in a shorter period of time. And that might be better at destroying the cancer cells, while limiting sides effects of the normal tissue."

In this Mayo Clinic Q&A podcast, Dr. Mutter expands on the research at Mayo Clinic's research and the development of new therapies to minimize patient side effects from radiation, including the increased use of proton therapy. Dr. Mutter also talks about the patient concerns about relapses and how Mayo is using medicines in combination with radiation to reduce relapse risks.

To practice safe social distancing during the COVID-19 pandemic, this interview was conducted using video conferencing. The sound and video quality are representative of the technology used. For the safety of its patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was recorded prior to COVID-19 or recorded in an area not designated for patient care, where social distancing and other safety protocols were followed.

Read the full transcript.

For more information and all your COVID-19 coverage, go to the Mayo Clinic News Network and mayoclinic.org.

Connect with others talking about the breast cancer and supporting one another in the Breast Cancer support group.

Please sign in or register to post a reply.